share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  08/07 13:36
Moomoo AI 已提取核心訊息
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.
Recursion Pharmaceuticals, Inc. 的一名官員和董事 Christopher Gibson 計劃於 2024 年 08 月 07 日賣出公司的 30,000 股 A 類股份,市值總計 213,000 美元。 這些股份最初於 2016 年 09 月 01 日作爲創始股份從發行人處獲得,是一種形式的補償。 計劃出售的這批股份是在已經出售一批總計 200,000 股,獲得總收益爲 1,618,500 美元的三個月後。
Recursion Pharmaceuticals, Inc. 的一名官員和董事 Christopher Gibson 計劃於 2024 年 08 月 07 日賣出公司的 30,000 股 A 類股份,市值總計 213,000 美元。 這些股份最初於 2016 年 09 月 01 日作爲創始股份從發行人處獲得,是一種形式的補償。 計劃出售的這批股份是在已經出售一批總計 200,000 股,獲得總收益爲 1,618,500 美元的三個月後。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息